Oncolytics Biotech extends pelareorep patent cover to late 2040s
Oncolytics Biotech has provided an update on its intellectual property strategy for pelareorep, announcing the issuance of new method of use patents in several countries and outlining plans to extend portfolio protection into the late 2040s. A corresponding US patent is expected to issue in the near term, the NASDAQ-listed company said.
The Calgary-founded, San Diego-based clinical-stage immunotherapy firm already holds manufacturing patent protection through 2044. The newly issued patents cover pelareorep's use as an immunotherapy for cancer, and the company says it intends to pursue further method of use patents addressing specific combination regimens, including pelareorep paired with checkpoint inhibitors and targeted therapies.
Accelerated examination and next-generation development
Oncolytics has three patent application families pending and plans to submit one of these to the US Patent and Trademark Office under its Track One prioritised examination programme this quarter. Track One is designed to bring an application to final disposition within approximately 12 months of prioritised status being granted, giving the company earlier visibility on protection scope ahead of clinical and partnership decisions. Prioritised status does not guarantee allowance.
In a separate workstream, Oncolytics is collaborating with an academic partner on a structurally modified form of the virus it calls "next generation" pelareorep. The company expects this research to underpin a composition of matter patent application, which, if granted, could provide up to 20 years of protection from the applicable filing date. The modified virus is intended to offer enhanced efficacy, though the company acknowledged this will require confirmation through further studies.
Chief executive Jared Kelly said the portfolio expansion was designed to protect "how pelareorep is manufactured, how it is used to treat cancer, and the innovations that could define its next generation," adding that existing manufacturing protection through 2044 formed a strong foundation for those efforts.
Market and competitive context
Oncolytic virotherapy occupies a distinctive corner of the broader cancer immunotherapy landscape. Unlike checkpoint inhibitors or CAR-T constructs, oncolytic viruses seek to directly replicate within tumour cells while simultaneously activating systemic immune responses. Pelareorep has been administered to more than 1,200 patients across multiple solid tumour types, and Oncolytics reports encouraging Phase 2 signals in metastatic breast cancer and first-line pancreatic cancer. The company is currently pursuing regulatory Fast Track designations from the FDA in colorectal, anal, and pancreatic cancers.
The IP announcement is strategically timed. Patent cliffs are a well-understood pressure point in biotech partnering discussions: a portfolio running to the late 2040s materially improves the attractiveness of any licensing or co-development deal Oncolytics may be seeking. The company has stated it is actively pursuing strategic partnerships to accelerate development. Several larger oncology players, including pharma and mid-cap biotech, have recently shown interest in novel tumour microenvironment modulators, and a credible IP moat could strengthen Oncolytics' negotiating position.
Whether the composition of matter patent for next-generation pelareorep is ultimately granted will be a key milestone to watch. Composition of matter claims are generally considered the strongest form of pharmaceutical patent protection, and their absence from the current portfolio for the base molecule is a gap the company is evidently working to close.